BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23196585)

  • 21. Characterization of a single nucleotide polymorphism in the ZNF9 gene and analysis of association with myotonic dystrophy type II (DM2) in the Italian population.
    Vallo L; Bonifazi E; Borgiani P; Novelli G; Botta A
    Mol Cell Probes; 2005 Feb; 19(1):71-4. PubMed ID: 15652222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2).
    Sallinen R; Vihola A; Bachinski LL; Huoponen K; Haapasalo H; Hackman P; Zhang S; Sirito M; Kalimo H; Meola G; Horelli-Kuitunen N; Wessman M; Krahe R; Udd B
    Neuromuscul Disord; 2004 Apr; 14(4):274-83. PubMed ID: 15019706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum.
    Day JW; Ricker K; Jacobsen JF; Rasmussen LJ; Dick KA; Kress W; Schneider C; Koch MC; Beilman GJ; Harrison AR; Dalton JC; Ranum LP
    Neurology; 2003 Feb; 60(4):657-64. PubMed ID: 12601109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeat-primed polymerase chain reaction in myotonic dystrophy type 2 testing.
    Radvansky J; Ficek A; Kadasi L
    Genet Test Mol Biomarkers; 2011 Mar; 15(3):133-6. PubMed ID: 21204698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uninterrupted CCTG tracts in the myotonic dystrophy type 2 associated locus.
    Radvanszky J; Surovy M; Polak E; Kadasi L
    Neuromuscul Disord; 2013 Jul; 23(7):591-8. PubMed ID: 23561036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of repetitive regions in myotonic dystrophy type 1 and 2.
    Carson NL
    Curr Protoc Hum Genet; 2009 Apr; Chapter 9():Unit 9.6. PubMed ID: 19360700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
    Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
    Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2.
    Valaperta R; Lombardi F; Cardani R; Fossati B; Brigonzi E; Merli I; Sansone V; Merletti G; Spina E; Meola G; Costa E
    Genet Test Mol Biomarkers; 2015 Dec; 19(12):703-9. PubMed ID: 26505324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland.
    Suominen T; Bachinski LL; Auvinen S; Hackman P; Baggerly KA; Angelini C; Peltonen L; Krahe R; Udd B
    Eur J Hum Genet; 2011 Jul; 19(7):776-82. PubMed ID: 21364698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does quantitative EMG differ myotonic dystrophy type 2 and type 1?
    Szmidt-Salkowska E; Gawel M; Lusakowska A; Nojszewska M; Lipowska M; Sulek A; Krysa W; Rajkiewicz M; Seroka A; Kaminska AM
    J Electromyogr Kinesiol; 2014 Oct; 24(5):755-61. PubMed ID: 25052913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and genetic analysis of the first known Asian family with myotonic dystrophy type 2.
    Nakayama T; Nakamura H; Oya Y; Kimura T; Imahuku I; Ohno K; Nishino I; Abe K; Matsuura T
    J Hum Genet; 2014 Mar; 59(3):129-33. PubMed ID: 24430576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RNA pathogenesis of the myotonic dystrophies.
    Day JW; Ranum LP
    Neuromuscul Disord; 2005 Jan; 15(1):5-16. PubMed ID: 15639115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
    Meola G; Cardani R
    Neurol Sci; 2017 Apr; 38(4):535-546. PubMed ID: 28078562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The myotonic dystrophies: molecular, clinical, and therapeutic challenges.
    Udd B; Krahe R
    Lancet Neurol; 2012 Oct; 11(10):891-905. PubMed ID: 22995693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Skeletal muscle features in myotonic dystrophy and sarcopenia: do similar nuclear mechanisms lead to skeletal muscle wasting?
    Malatesta M
    Eur J Histochem; 2012 Aug; 56(3):e36. PubMed ID: 23027352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive conduction disturbance in myotonic dystrophy.
    Palazzolo J; Trucco E; Arce M; Riera AR; Femenía F
    Cardiol J; 2011; 18(3):322-5. PubMed ID: 21660927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myotonic dystrophies type 1 and 2: a summary on current aspects.
    Schara U; Schoser BG
    Semin Pediatr Neurol; 2006 Jun; 13(2):71-9. PubMed ID: 17027856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy.
    Logigian EL; Ciafaloni E; Quinn LC; Dilek N; Pandya S; Moxley RT; Thornton CA
    Muscle Nerve; 2007 Apr; 35(4):479-85. PubMed ID: 17230537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients.
    Santoro M; Fontana L; Maiorca F; Centofanti F; Massa R; Silvestri G; Novelli G; Botta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):917-924. PubMed ID: 29291944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
    Liquori CL; Ricker K; Moseley ML; Jacobsen JF; Kress W; Naylor SL; Day JW; Ranum LP
    Science; 2001 Aug; 293(5531):864-7. PubMed ID: 11486088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.